- Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance. [Clinical Trial, Phase II]
- CONCLUSIONS: When complete, CARMAN will provide important information on efficacy and safety in first-line CAR-T cell therapy in hr MCL and has the potential to prepare a practice changing confirmatory trial for these difficult-to-treat patients. Recruitment is ongoing.
- Publisher Full Text (DOI)
- DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy. [Randomized Controlled Trial]
- CONCLUSIONS: This trial investigates whether the in vitro cooperativity of DAC, VEN, and ATRA prolongs OS in unfit AML patients compared to placebo, offering a novel, low-toxicity triplet combination with a promising risk-benefit ratio.
- PMC Free PDF
- Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards. [Journal Article]
- CONCLUSIONS: Both models demonstrated high agreement with expert GIST MTB recommendations, with no significant performance difference between them. Diagnostic reasoning represented the weakest domain, reflecting the challenge of reconstructing context-dependent workup decisions from tumor board documentation. These findings support a potential assistive role for LLMs in GIST MTB workflows, while underscoring the continued necessity of expert oversight.
- PMC Free PDF
- Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF). [Clinical Trial, Phase II]
- CONCLUSIONS: Initiation of TTFields before and during radiotherapy was feasible and was not associated with protocol-defined treatment-limiting toxicity in the Arm A cohort. Because the TLT definition was narrow and efficacy analyses were exploratory and exposure-conditioned, these findings should be interpreted as feasibility data rather than evidence of improved tumor control or survival. The results support randomized evaluation of earlier TTFields integration in newly diagnosed glioblastoma.
- PMC Free PDF
- Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models. [Journal Article]
- CONCLUSIONS: The combination of fruquintinib and TAS-102 improved antitumor activity in CRC and GC xenograft models, with in vitro evidence of enhanced anti-angiogenic activity of fruquintinib by trifluridine and ex vivo evidence of an increased amount of intratumor trifluridine with fruquintinib. Our data support testing the combination of fruquintinib and TAS-102 in clinical studies.
- PMC Free PDF